Methicillin-resistant Staphylococcus aureus-induced thrombo-inflammatory response is reduced with timely antibiotic administration

Summary

Methicillin-resistant Staphylococcus aureus (MRSA) induces a prothrombotic and pro-inflammatory milieu. Although timely antibiotic administration in MRSA sepsis may improve outcomes by arresting bacterial growth, the effects of antibiotics on mitigating injurious thrombo-inflammatory cellular responses remains unexplored. Using a newly developed human whole blood model and an in vivo mouse model of MRSA infection, we examined how antibiotics inhibit MRSA induced thrombo-inflammatory pathways. Human whole blood was inoculated with MRSA. Thrombin generation and inflammatory cytokine synthesis was measured in the presence or absence of linezolid and vancomycin. C57BL/6 mice were injected with MRSA and the effect of vancomycin administration was examined. MRSA accelerated thrombin generation in a time- and concentration-dependent manner and induced the release of cytokines, including interleukin (IL)-6, IL-8, and monocyte chemotactic protein (MCP)-1. The increase in thrombin generation and inflammatory responses was mediated through the synthesis of tissue factor and cytokines, respectively, and the release of microparticles. The early administration of antibiotics restored normal thrombin generation patterns and significantly reduced the synthesis of cytokines. In contrast, when antibiotic administration was delayed, thrombin generation and cytokine synthesis were not significantly reduced. In mice infected with MRSA, early antibiotic administration reduced thrombin anti-thrombin complexes and cytokine synthesis, whereas delayed antibiotic administration did not. These data provide novel mechanistic evidence of the importance of prompt antibiotic administration in infectious syndromes.

Keywords

Thrombin - tissue factor - cytokines - methicillin-resistant Staphylococcus aureus - antibiotics

^# These authors contributed equally.

• References

• 1 Armstrong PC, Hu H, Rivera J. et al. Staphylococcal superantigen-like protein 5 induces thrombotic and bleeding complications in vivo: Inhibition by an anti-SSL5 antibody and the glycan Bimosiamose. J Thromb Haemost. 2012 epub ahead of print.
• 2 Nguyen T, Kyle UG, Jaimon N. et al. Coinfection with Staphylococcus aureus increases risk of severe coagulopathy in critically ill children with influenza A (H1N1) virus infection. Crit Care Med 2012; 40: 3246-3250.
• 3 Martin E, Cevik C, Nugent K. The role of hypervirulent Staphylococcus aureus infections in the development of deep vein thrombosis. Thromb Res 2012; 130: 302-308.
• 4 Cesar S, Garcia A, Parada E. et al. Cavernous sinus thrombosis due to invasive community-associated methicillin-resistant Staphylococcus aureus infection. Enferm Infecc Microbiol Clin 2010; 28: 755-756.
• 5 Vardakas KZ, Matthaiou DK, Falagas ME. Comparison of community-acquired pneumonia due to methicillin-resistant and methicillin-susceptible Staphylococcus aureus producing the Panton-Valentine leukocidin. Int J Tuberc Lung Dis 2009; 13: 1476-1485.
• 6 Arai H, Hanai H, Furuta T. et al. A patient who survived total colonic type ulcerative colitis complicated by toxic megacolon, disseminated intravascular coagulation, methicillin-resistant Staphylococcus aureus infection and bilateral femoral phlebothrombosis. J Gastroenterol 1999; 34: 395-399.
• 7 McAdow M, Kim HK, Dedent AC. et al. Preventing Staphylococcus aureus sepsis through the inhibition of its agglutination in blood. PLoS Pathog 2011; 07: e1002307.
• 8 Mattsson E, Herwald H, Bjorck L. et al. Peptidoglycan from Staphylococcus aureus induces tissue factor expression and procoagulant activity in human monocytes. Infect Immun 2002; 70: 3033-3039.
• 9 Mattsson E, Herwald H, Egesten A. Superantigens from Staphylococcus aureus induce procoagulant activity and monocyte tissue factor expression in whole blood and mononuclear cells via IL-1 beta. J Thromb Haemost 2003; 01: 2569-2576.
• 10 Mattsson E, Heying R, van de Gevel JS. et al. Staphylococcal peptidoglycan initiates an inflammatory response and procoagulant activity in human vascular endothelial cells: a comparison with highly purified lipoteichoic acid and TSST-1. FEMS Immunol Med Microbiol 2008; 52: 110-117.
• 11 Kang HJ, Ha JM, Kim HS. et al. The role of phagocytosis in IL-8 production by human monocytes in response to lipoproteins on Staphylococcus aureus. Biochem Biophys Res Commun 2011; 406: 449-453.
• 12 Ikejima T, Dinarello CA, Gill DM. et al. Induction of human interleukin-1 by a product of Staphylococcus aureus associated with toxic shock syndrome. J Clin Invest 1984; 73: 1312-1320.
• 13 Ahn JY, Song JY, Yun YS. et al. Protection of Staphylococcus aureus-infected septic mice by suppression of early acute inflammation and enhanced antimicrobial activity by ginsan. FEMS Immunol Med Microbiol 2006; 46: 187-197.
• 14 Masuta K, Oba Y, Iwata K. Linezolid vs Vancomycin for Methicillin-Resistant Staphylococcus aureus Nosocomial Pneumonia: Controversy continues. Clin Infect Dis 2012; 55: 161.
• 15 Wunderink RG, Rello J, Cammarata SK. et al. Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest 2003; 124: 1789-1797.
• 16 Kumar A, Roberts D, Wood KE. et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006; 34: 1589-1596.
• 17 Kollef MH, Shorr A, Tabak YP. et al. Epidemiology and outcomes of healthcare-associated pneumonia: results from a large US database of culture-positive pneumonia. Chest 2005; 128: 3854-3862.
• 18 Kollef MH, Ward S. The influence of mini-BAL cultures on patient outcomes: implications for the antibiotic management of ventilator-associated pneumonia. Chest 1998; 113: 412-420.
• 19 Garcia-Roca P, Mancilla-Ramirez J, Santos-Segura A. et al. Linezolid diminishes inflammatory cytokine production from human peripheral blood mononuclear cells. Arch Med Res 2006; 37: 31-35.
• 20 Lambers C, Burian B, Binder P. et al. Early immunomodulatory effects of linezolid in a human whole blood endotoxin model. Int J Clin Pharmacol Ther 2010; 48: 419-424.
• 21 Kushiya K, Nakagawa S, Taneike I. et al. Inhibitory effect of antimicrobial agents and anisodamine on the staphylococcal superantigenic toxin-induced overproduction of proinflammatory cytokines by human peripheral blood mononuclear cells. J Infect Chemother 2005; 11: 192-195.
• 22 Pichereau S, Moran JJ, Hayney MS. et al. Concentration-dependent effects of antimicrobials on Staphylococcus aureus toxinmediated cytokine production from peripheral blood mononuclear cells. J Antimicrob Chemother 2012; 67: 123-129.
• 23 de Vos AF, Pater JM, van den Pangaart PS. et al. In vivo lipopolysaccharide exposure of human blood leukocytes induces cross-tolerance to multiple TLR ligands. J Immunol 2009; 183: 533-542.
• 24 Kikkert R, de Groot ER, Aarden LA. Cytokine induction by pyrogens: comparison of whole blood, mononuclear cells, and TLR-transfectants. J Immunol Methods 2008; 336: 45-55.
• 25 Dragneva Y, Anuradha CD, Valeva A. et al. Subcytocidal attack by staphylococcal alpha-toxin activates NF-kappaB and induces interleukin-8 production. Infect Immun 2001; 69: 2630-2635.
• 26 Lacroix R, Robert S, Poncelet P. et al. Standardization of platelet-derived microparticle enumeration by flow cytometry with calibrated beads: results of the International Society on Thrombosis and Haemostasis SSC Collaborative workshop. J Thromb Haemost 2010; 08: 2571-2574.
• 27 Robert S, Poncelet P, Lacroix R. et al. Standardization of platelet-derived micro-particle counting using calibrated beads and a Cytomics FC500 routine flow cy-tometer: a first step towards multicenter studies?. J Thromb Haemost 2009; 07: 190-197.
• 28 Aleman MM, Gardiner C, Harrison P. et al. Differential contributions of monocyte- and platelet-derived microparticles towards thrombin generation and fibrin formation and stability. J Thromb Haemost 2011; 09: 2251-2261.
• 29 Wang JG, Manly D, Kirchhofer D. et al. Levels of microparticle tissue factor activity correlate with coagulation activation in endotoxemic mice. J Thromb Haemost 2009; 07: 1092-1098.
• 30 Campbell RA, Fischer TH, Wolberg AS. A novel approach to improving recombinant factor VIIa activity with a preserved platelet preparation. Br J Haematol 2007; 138: 82-93.
• 31 Campbell RA, Overmyer KA, Selzman CH. et al. Contributions of extravascular and intravascular cells to fibrin network formation, structure, and stability. Blood 2009; 114: 4886-4896.
• 32 Schwertz H, Koster S, Kahr WH. et al. Anucleate platelets generate progeny. Blood 2011; 115: 3801-3809.
• 33 Domenech A, Ribes S, Cabellos C. et al. Experimental study on the efficacy of combinations of glycopeptides and beta-lactams against Staphylococcus aureus with reduced susceptibility to glycopeptides. J Antimicrob Chemother 2005; 56: 709-716.
• 34 McDevitt D, Nanavaty T, House-Pompeo K. et al. Characterization of the interaction between the Staphylococcus aureus clumping factor (ClfA) and fibrinogen. Eur J Biochem 1997; 247: 416-424.
• 35 Bokarewa MI, Tarkowski A. Thrombin generation and mortality during Staphylococcus aureus sepsis. Microb Pathog 2001; 30: 247-252.
• 36 Levi M, van der Poll T, ten Cate H. Tissue factor in infection and severe inflammation. Semin Thromb Hemost 2006; 32: 33-39.
• 37 Zimmerman GA, McIntyre TM, Prescott SM. et al. The platelet-activating factor signaling system and its regulators in syndromes of inflammation and thrombosis. Crit Care Med 2002; 30 (05) Suppl S294-301.
• 38 Bernardo K, Pakulat N, Fleer S. et al. Subinhibitory concentrations of linezolid reduce Staphylococcus aureus virulence factor expression. Antimicrob Agents Chemother 2004; 48: 546-555.
• 39 Pichereau S, Pantrangi M, Couet W. et al. Simulated antibiotic exposures in an in vitro hollow-fiber infection model influence toxin gene expression and production in community-associated methicillin-resistant Staphylococcus aureus strain MW2. Antimicrob Agents Chemother 2012; 56: 140-147.
• 40 Levi M, de Jonge E, van der Poll T. Sepsis and disseminated intravascular coagulation. J Thromb Thrombolysis 2003; 16: 43-47.
• 41 Dixon B. The role of microvascular thrombosis in sepsis. Anaesth Intensive Care 2004; 32: 619-629.
• 42 Leifsson PS, Iburg T, Jensen HE. et al. Intravenous inoculation of Staphylococcus aureus in pigs induces severe sepsis as indicated by increased hypercoagulability and hepatic dysfunction. FEMS Microbiol Lett 2010; 309: 208-216.
• 43 ten Cate H, Timmerman JJ, Levi M. The pathophysiology of disseminated intravascular coagulation. Thromb Haemost 1999; 82: 713-717.
• 44 Dempfle CE. Disseminated intravascular coagulation and coagulation disorders. Curr Opin Anaesthesiol 2004; 17: 125-129.
• 45 Dempfle CE. Coagulopathy of sepsis. Thromb Haemost 2004; 91: 213-224.
• 46 Levi M, Ten Cate H. Disseminated intravascular coagulation. N Engl J Med 1999; 341: 586-592.
• 47 Miner JR, Heegaard W, Mapes A. et al. Presentation, time to antibiotics, and mortality of patients with bacterial meningitis at an urban county medical center. J Emerg Med 2001; 21: 387-392.
• 48 Kollef MH, Rello J, Cammarata SK. et al. Clinical cure and survival in Grampositive ventilator-associated pneumonia: retrospective analysis of two double-blind studies comparing linezolid with vancomycin. Intensive Care Med 2004; 30: 388-394.
• 49 Larche J, Azoulay E, Fieux F. et al. Improved survival of critically ill cancer patients with septic shock. Intensive Care Med 2003; 29: 1688-1695.
• 50 Nobre V, Sarasin FP, Pugin J. Prompt antibiotic administration and goal-directed hemodynamic support in patients with severe sepsis and septic shock. Curr Opin Crit Care 2007; 13: 586-591.